IART stock: buy or sell?
May 21st, 2019
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.
Should I buy IART stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Integra LifeSciences stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Integra LifeSciences stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we collected 5 ratings published for IART stock in the last 30 days. The general sentiment of these ratings is bullish for IART stock, with 4 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
IART stock analysis
Integra LifeSciences appreciated a tiny 0.59% and closed at $49.76.
Integra LifeSciences shares appreciated 0.59% to $49.76 today. Since SMA50d and SMA100d crossed up on March, IART price slid a -13.20%.
After sliding a frightening -6.37% in a week last week, Integra LifeSciences closed this week at $49.76 and gained a slightly fine 0.67%.
Since price and 40-weeks moving average lines crossed down late October 2018, IART fell $-11.29 per share (-18.49%). Stocks below the 40w moving average line are usually not recommended for average traders. Far behind is the all-time high Integra LifeSciences marked by mid June 2018 and since then the price is -26.28% below that top.
IART stock price history
IART IPO was on August 16th, 1995 at $7.75 per share1. Since then, IART stock surged a 542.10%, with a yearly average of 23.60%. If you had invested right after IART's IPO a $1,000 in IART stock in 1995, it would worth $5,421.00 today.
1: Adjusted price after possible price splits or reverse-splits.
IART stock historical price chart
IART stock reached all-time highs on June with a price of $67.50.
IART stock price target is $59.00How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' IART stock price predictions in the hope that they will be met as they may be wrong and not met. We found 3 price targets for Integra LifeSciences stock published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Integra LifeSciences reported its latest financial data, posting a slightly good climb for the Earnings per Share (EPS). Analyst expected $0.62 per share, but Integra LifeSciences posted $0.65.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an astounding gain of 23.92% to $1,472.44 million USD. By contrast, its income margin (compared to sales) depreciated to 4.13%, that is $60.80 million.
|2013||$836 M||-||$-16.98 M-2.0%||-|
|2014||$928 M||11.01%||$34 M3.7%||-300.26%|
|2015||$883 M||-4.91%||$-3.52 M-0.4%||-110.35%|
|2016||$992 M||12.39%||$75 M7.5%||-2,218.90%|
|2017||$1,188 M||19.77%||$65 M5.4%||-13.17%|
|2018||$1,472 M||23.92%||$61 M4.1%||-6.09%|
Quarterly financial resultsIntegra LifeSciences posted $383.32 million in sales for 2018-Q4, a 4.77% improvement compared to previous quarter. Reported quarter income marked $25.14 M with a profit margin of 6.56%. Profit margin raised a 2.92% compared to previous quarter when profit margin was 3.63%. When comparing turnover to same quarter last year, Integra LifeSciences sales marked a fine growth and inched a 3.99%.
|2017-Q2||$282 M||-||$11 M3.8%||-|
|2017-Q3||$279 M||-1.18%||$3 M1.1%||-70.86%|
|2017-Q4||$369 M||32.19%||$44 M12.0%||1,304.08%|
|2018-Q1||$357 M||-3.13%||$11 M3.1%||-75.22%|
|2018-Q2||$366 M||2.55%||$11 M3.1%||3.49%|
|2018-Q3||$366 M||-0.09%||$13 M3.6%||16.87%|
|2018-Q4||$383 M||4.77%||$25 M6.6%||89.08%|
|2019-Q1||$360 M||-6.16%||$33 M9.1%||30.30%|
Integra LifeSciences ownershipWhen you are planning to buy a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Integra LifeSciences, 17.28% of all outstanding shares are owned by its staff.
Bearish positions for IART stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$4.3 B||$14.0 B||$2.3 B||$368.2 B||$117.6 B|
|Total shares||85.5 M||298.1 M||28.2 M||2,660.0 M||1,340.0 M|
|Float shares||70.6 M||297.1 M||27.4 M||2,650.0 M||1,340.0 M|
|- Institutional holdings (%)||85.1%||92.4%||97.5%||69.2%||84.2%|
|- Insider holdings (%)||17.3%||0.3%||1.8%||0.1%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$49.72 - $50.41|
|Average true range||$1.47|
|50d mov avg||$53.28|
|100d mov avg||$51.23|
|200d mov avg||$54.59|
Integra LifeSciences performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Cardinal Health, CONMED, , Medtronic, RTI Surgical, Stryker, Teleflex, DENTSPLY SIRONA and Zimmer Biomet as the bechmarking frame for Integra LifeSciences stock.